Chang Ki Min
- Hematology top 5%
- Multiple Myeloma Research and Treatments 16
- Hematopoietic Stem Cell Transplantation 7
- Chronic Myeloid Leukemia Treatments 4
- Acute Myeloid Leukemia Research 3
- Genetics top 10%
-
- Cancer Treatment and Pharmacology 5
- Peptidase Inhibition and Analysis 4
-
- Protein Degradation and Inhibitors 4
- Ubiquitin and proteasome pathways 3
- Co-authors
- Seok LeeNam Jin YooSug Hyung LeeYeun Jun ChungEun Goo JeongMin Sung KimJung Im JungSeong Tai Hahn
- Cited by
- HematologyGeneticsOncology
- Journals
- Proceedings of the National Academy of Sciences (1 paper)Journal of Clinical Oncology (4 papers)Blood (5 papers)
- Partner nations
- South KoreaUnited StatesJapan
In The Last Decade
Chang Ki Min
34 papers receiving 411 citations
Peers
Comparison fields: 5 of 69
- Hematology 177
- Genetics 95
- Oncology 163
- Immunology 77
- Biological Psychiatry 7
Countries citing papers authored by Chang Ki Min
This map shows the geographic impact of Chang Ki Min's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chang Ki Min with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chang Ki Min more than expected).
Fields of papers citing papers by Chang Ki Min
This network shows the impact of papers produced by Chang Ki Min. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chang Ki Min. The network helps show where Chang Ki Min may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Chang Ki Min, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 0 | |
| 2 | 2023 | 0 | |
| 3 | 2022 | 5 | |
| 4 | 2022 | 17 | |
| 5 | 2021 | 27 | |
| 6 | 2021 | 5 | |
| 7 | 2019 | 4 | |
| 8 | 2016 | 16 | |
| 9 | 2011 | 6 | |
| 10 | 2010 | 25 | |
| 11 | 2009 | 1 | |
| 12 | 2009 | 10 | |
| 13 | 2008 | 5 | |
| 14 | 2008 | 1 | |
| 15 | 2007 | 3 | |
| 16 | Design and Implementation of Individual Tree Growth Visualization System of Larch(Larix olgensis) | 2006 | 2 |
| 17 | Itraconazole Oral Solution versus Fluconazole Syrup for Prevention of Invasive Fungal Infections in Patients Receiving Hematopoietic Stem Cell Transplantation: Prospective, Randomized, Comparative Clinical Trial | 2005 | 7 |
| 18 | 2002 | 8 | |
| 19 | Safety and Pharmacokinetics of Intravenous Busulfan as Conditioning prior to Allogeneic Stem Cell Transplantation | 2002 | 1 |
| 20 | 2000 | 2 |
About Chang Ki Min
Chang Ki Min is a scholar working on Hematology, Transplantation and Oncology, having authored 38 papers that have together received 416 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (16 papers), Hematopoietic Stem Cell Transplantation (7 papers), Cancer Treatment and Pharmacology (5 papers), Peptidase Inhibition and Analysis (4 papers), Chronic Myeloid Leukemia Treatments (4 papers), Protein Degradation and Inhibitors (4 papers), Ubiquitin and proteasome pathways (3 papers) and Acute Myeloid Leukemia Research (3 papers). The work is most often cited by research in Hematology (177 citations), Genetics (95 citations) and Oncology (163 citations). Chang Ki Min has collaborated with scholars based in South Korea, United States and Japan. Frequent co-authors include Seok Lee, Nam Jin Yoo, Sug Hyung Lee, Yeun Jun Chung, Eun Goo Jeong, Min Sung Kim, Jung Im Jung, Seong Tai Hahn, Seog Hee Park and Yoo Jin Kim. Their work appears in journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.